Facilitating European Clinical Research

ECRIN is a public, non-profit organisation that links scientific partners and networks across Europe
to facilitate multinational clinical research. We provide sponsors and investigators with advice,
management services and tools to overcome hurdles to multinational trials and enhance collaboration.

Our Work

We provide our nine Member and Observer Countries with diverse trial support services
and contribute to other capacity building projects with additional European and international partners.

ECRIN in Numbers

Member & Observer Countries

Million citizens represented

Trials in ECRIN portfolio

Average # of countries per trial

Events

Date:

The next CORBEL Medical Infrastructure Users Forum (www.corbel-project.eu) will be held in Paris on 15 October, 2018.

The forum is meant to promote collaboration between research communities, funding bodies and medical research infrastructures; this year the event will focus on emerging technologies in the context of big data and personalised/stratified medicine

The conference will represent the opportunity to raise awareness of medical RIs and exchange with scientific communities

Agenda and registration form; registration is free but mandatory 

Date:

CORBEL-Logo strapline.jpgCORBEL's next Annual General Meeting will take place from 16 to 17 October in Paris.  

The CORBEL project aims to establish shared services between the European Strategy Forum on Research Infrastructures Biological and Medical Sciences Research Infrastructures (ESFRI BMS RIs)–which includes ECRIN–for the biomedical research community. 

Learn more

CORBEL website

ECRIN capacity building project page (including a brief description of CORBEL)

 

Flag_of_Europe.svg.png CORBEL is funded by the European Union Horizon 2020 research and innovation programme (grant agreement no. 654248).

Date:

The inaugural Keystone Symposium About Rare Diseases will take place at the Vienna BioCenter from 11 to 14 November 2018.
The conference will examine the current and future bottlenecks to gene discovery, disease modeling, and therapeutic approaches for the estimated 7,000 known rare diseases, and suggest strategies to accelerate progress in this regard. 

Learn more